iiinova — where your digital self keeps evolving

Prolynx

@prolynxinc.com

Prolynx develops ultra-long-acting medicines for obesity and metabolic diseases, advancing extended-duration therapeutics for monthly and quarterly dosing to support more consistent long-term treatment.

Posts Replies Media

Prolynx @prolynxinc.com · 19/12/2025

ICYMI: We welcomed Chris Boulton as CEO and announced a $70M Series A to advance ultra-long-acting therapies for obesity and metabolic disease. We’re encouraged by the engagement around our extended-duration approaches and look forward to sharing continued progress. #medsky bit.ly/4a6LdhP

000

Prolynx @prolynxinc.com · 11/12/2025

Prolynx has raised a $70M Series A & appointed Chris Boulton as CEO. Backed by 5AM Ventures, OrbiMed, and Monograph Capital, we’re advancing ultra-long-acting therapies designed for monthly and quarterly dosing in obesity & metabolic diseases. More: bit.ly/4a6LdhP #biosky

030